{'52WeekChange': -0.3138196,
 'SandP52WeekChange': 0.0644362,
 'address1': '7 Golda Meir Street',
 'address2': 'Weizmann Science Park',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 7.16,
 'askSize': 800,
 'averageDailyVolume10Day': 32450,
 'averageVolume': 22258,
 'averageVolume10days': 32450,
 'beta': 1.61258,
 'beta3Year': None,
 'bid': 7.13,
 'bidSize': 1000,
 'bookValue': 2.982,
 'category': None,
 'circulatingSupply': None,
 'city': 'Ness Ziona',
 'companyOfficers': [],
 'country': 'Israel',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 7.26,
 'dayLow': 7.1,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.699,
 'enterpriseToRevenue': 4.83,
 'enterpriseValue': 96657592,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '972 8 931 3434',
 'fiftyDayAverage': 8.1524,
 'fiftyTwoWeekHigh': 21,
 'fiftyTwoWeekLow': 5,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 8266194,
 'forwardEps': -1.3,
 'forwardPE': -5.5076923,
 'fromCurrency': None,
 'fullTimeEmployees': 61,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.70798,
 'heldPercentInstitutions': 0.13964,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/sol-gel.com',
 'longBusinessSummary': 'Sol-Gel Technologies Ltd., a clinical stage specialty '
                        'pharmaceutical company, focuses on developing and '
                        'commercializing topical dermatological drug products '
                        'based on its proprietary microencapsulation delivery '
                        "system in Israel. The company's lead product "
                        'candidates include Twyneo, which has completed Phase '
                        'II clinical trials for the treatment of acne '
                        'vulgaris; Epsolay that has completed Phase II '
                        'clinical trials for the treatment of papulopustular '
                        'rosacea; SGT-210, a epidermal growth factor receptor '
                        'inhibitor, which is in development for the treatment '
                        'of palmoplantar keratoderma and non-melanoma skin '
                        'cancer; and tapinarof and roflumilast to treat '
                        'psoriasis and other dermatological indications. It is '
                        'also involved in the development of generic topical '
                        'dermatological drug products. Sol-Gel Technologies '
                        'Ltd. has collaboration with Perrigo; and Douglas '
                        'Pharmaceuticals for the development and '
                        'commercialization of a generic product candidate. The '
                        'company was founded in 1997 and is headquartered in '
                        'Ness Ziona, Israel.',
 'longName': 'Sol-Gel Technologies Ltd.',
 'market': 'us_market',
 'marketCap': 164485968,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_621569',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -25991000,
 'nextFiscalYearEnd': 1640908800,
 'open': 7.26,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '972 8 931 3433',
 'previousClose': 7.33,
 'priceHint': 2,
 'priceToBook': 2.401073,
 'priceToSalesTrailing12Months': 8.219777,
 'profitMargins': -1.2988299,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 7.26,
 'regularMarketDayLow': 7.1,
 'regularMarketOpen': 7.26,
 'regularMarketPreviousClose': 7.33,
 'regularMarketPrice': 7.26,
 'regularMarketVolume': 23828,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 22972900,
 'sharesPercentSharesOut': 0.0056,
 'sharesShort': 128580,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 61921,
 'shortName': 'Sol-Gel Technologies Ltd.',
 'shortPercentOfFloat': 0.0145000005,
 'shortRatio': 5.34,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'SLGL',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.291,
 'twoHundredDayAverage': 9.249454,
 'volume': 23828,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.sol-gel.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '7403650'}